Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
TrioxNano
TrioxNano Overview
TrioxNano's powerhouse created a biosphere of programmed therapeutic/diagnostic solutions based on synthetic DNA molecular machines Our team of exceptional scientists fluent in the secrets of DNA programming & highly skilled execs has led to the development of the Programmed Medicine Biosphere. Granted global all inclusive patents & winning the prestigious H2020 2.7M grant allowed us develop :
P-ADC - Programmable ADCs (Aptamer DNAzyme Conjugates) Technology: Market Challenges: Analog treatments exhibit low efficacy and high toxicity, addressing only 15% of cancer targets. Our Solution: P-ADC replaces analog components with a digital aptamer and programmed DNAzyme, excelling in highly targeted mRNA knockdown. Market Potential: Estimated at $550B, addressing the growing need for precision medicine.
P-DDP - Programmable Drug Delivery Platforms: Market Challanges: Traditional drug delivery lacks precision, leading to low treatment effectiveness and side effects. Our Solution: P-DDP enables precise drug delivery, significantly improving efficacy and reducing side effects. Market Potential: Estimated at $100B, capitalizing on the demand for personalized medicine.
P-DST - Programmable DNA Strip Technology: Market Challanges: Current antigen tests lack sensitivity, specificity, and home-testing capabilities. Our Solution: P-DST revolutionizes antigen testing with a programmable approach, offering at-home testing for thousands of antigens. Market Potential: Annual revenues estimated at $140B, meeting the increasing demand for accurate home diagnostics.
PCPM - Precision Cancer Profiling using mRNA Knockdown Technology: Market Challanges: Current cancer tests lack functional insights, precision, and cost-effectiveness. Our Solution: PCPM provides functional information, cost-effective mRNA profiling, and AI + ML recommendations for a holistic understanding. Market Potential: Exceeding $100B, addressing the rising need for functional cancer diagnostics.